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Optimizing Cutoff Scores for the Barthel Index and the
Modified Rankin Scale for Defining Outcome in Acute
Stroke Trials
Maarten Uyttenboogaart, MD; Roy E. Stewart, MSc; Patrick C.A.J. Vroomen, MD, PhD;
Jacques De Keyser, MD, PhD; Gert-Jan Luijckx, MD, PhD
Background and Purpose—There is little agreement on how to assess outcome in acute stroke trials. Cutoff scores for the
Barthel Index (BI) and modified Rankin Scale (mRS) are frequently arbitrarily chosen to dichotomize favorable and
unfavorable outcome. We investigated sensitivity and specificity of BI cutoff scores in relation to the mRS to obtain the
optimal corresponding BI and mRS scores.
Methods—BI and mRS scores were collected from 1034 ischemic stroke patients. Sensitivity and specificity were
calculated for BI cutoff scores from 45 to 100 in mRS score 1, 2, and 3 and were plotted in receiver operator
characteristic (ROC) curves.
Results—The cutoff scores for the BI with the highest sum of sensitivity and specificity were 95 (sensitivity 85.6%;
specificity 91.7%), 90 (sensitivity 90.7%; specificity 88.1%), and 75 (sensitivity 95.7%; specificity, 88.5%) for,
respectively, mRS 1, 2, and 3. The area under the ROC curve was 0.933 in mRS 1, 0.960 in mRS 2, and 0.979 in
mRS 3.
Conclusions—The optimal cutoff scores for the BI were 95 for mRS 1, 90 for mRS 2, and 75 for mRS 3. For future acute
stroke trials that assess stroke outcome with the BI and mRS, we recommend the use of these BI cutoff score(s) with
the corresponding mRS cutoff score(s), to ensure the use of consistent and uniform end points. (Stroke. 2005;36:
1984-1987.)
Key Words: disability evaluation  outcome assessment  stroke
Several randomized controlled acute stroke trials havebeen designed to investigate effectiveness of therapeutic
interventions. A major point of discussion is how to define
outcome in acute stroke trials with disability and handicap
scales.1–6 The most widely used scales are the modified
Rankin Scale (mRS) and the Barthel Index (BI).
The mRS has proved to be valid and reliable for defining
outcome in stroke patients.7,8 Although the mRS was
designed as a handicap scale,9 it should be considered a
disability scale.10 The mRS defines 6 different grades
of disability, from 0 for “no symptoms at all” to 5 for “severe
disability or bedridden, incontinent, and requiring constant
nursing care and attention,” and grade 6 for death.
The BI has also shown to be valid and reliable for
assessing disability in stroke patients.8,11 It contains 10
items with varying weights that score activities of daily
living (ADL). The items bathing and grooming are scored
0 or 5; the items feeding, dressing, controlling bladder,
controlling bowel, getting onto and off the toilet, and
ascending and descending stairs are scored 0, 5, or 10.
Items regarding moving from wheelchair to bed and
walking on level surface are scored 0, 5, 10, or 15. The
total BI is a cumulative score of the 10 items, with a
maximum score of 100 corresponding with complete
independence, and a minimum score of 0 corresponding
with total dependence.
There is little consensus on the optimal implementation of
the BI and mRS as outcome measure in acute stroke trials. It
is unclear which outcome scale is preferable. Moreover, the
cutoff scores distinguishing favorable and unfavorable out-
come are highly variable between various acute stroke trials.4
This issue has great consequences for the design and inter-
pretation of acute stroke trials. The BI has a larger score range
and therefore more possible cutoff scores compared with the
mRS. Less is known which BI scores are corresponding with
the different mRS scores. There have been only a few studies
that determined pivotal BI cutoff scores, and none of them
were related to the mRS.12–14 In this article, we investigated
which cutoff scores on the BI corresponded to mRS grades 1,
2, and 3.
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Subjects and Methods
Population and Data Collection
Data were obtained from the United States and Canadian Lubeluzole
Ischemic Stroke Study (INT-LUB-9) and the European and Austra-
lian Lubeluzole Ischemic Stroke Study (INT-LUB-5),15,16 provided
by the Janssen Research Foundation (Beerse, Belgium). These trials
have been published respectively in 1997 and 1998. In summary,
these trials studied the neuroprotective effect of lubeluzole in acute
ischemic stroke. In both trials, there was no significant difference in
mortality rate (primary end point) between lubeluzole-treated pa-
tients and placebo-treated patients.
The INT-LUB-5 study included 725 stroke patients (675 ischemic
and 50 hemorrhagic), and the INT-LUB-9 included 721 patients (700
ischemic stroke and 21 nonischemic stroke or other causes). BI and
mRS scores from ischemic stroke patients at 12 weeks after stroke
onset were analyzed. Dead patients were excluded because our
analysis focused on disability scores of the BI and mRS. We did not
make a distinction between lubeluzole-treated and placebo-treated
patients because the intention was only to study the relationship
between BI and mRS scores. At 12 weeks, 519 corresponding BI and
mRS scores were present in INT-LUB-9 and 515 in INT-LUB-5,
forming a total of 1034 BI and mRS scores.
Analysis Methods
Outcome was dichotomized into favorable and unfavorable using 3
different mRS scores to obtain the corresponding BI score for each
mRS score. An mRS score 1, 2, or 3 reflected favorable outcome,
and an mRS score1, 2, or 3 reflected unfavorable outcome. The BI
cutoff scores were defined as BI 45 to 100 for favorable outcome
and as BI 45 to 100 for unfavorable outcome. Sensitivity was
expressed as the rate of unfavorable outcome according to the mRS
and BI. Specificity was expressed as the rate of favorable outcome
according to the BI and mRS (Table 1).
The maximal distinction between favorable and unfavorable
outcome defined by the mRS is reached when the sensitivity and
specificity of a BI score are maximal because false favorable and
false unfavorable outcome rates were considered to be equally
important. This corresponds with the BI score that has the highest
sum of sensitivity and specificity.17 To investigate the relationship
between sensitivity and specificity, receiver operator characteristic
(ROC) curves were obtained and the areas under the curve (AUCs)
were calculated. ROC curves plot sensitivity versus 1-specificity and
visualize the optimal cutoff scores for the BI in each mRS grade. The
AUC indicates the discriminative properties between favorable and
unfavorable outcome for the BI cutoff scores in the 3 mRS scores.
Results
Population Characteristics
From the 1034 patients, 547 (52.9%) were female. The mean
age was 69.1 years (SD 12.8 years). Median BI score was
80 with an interquartile range from 40 to 100. The mRS score
distribution was mRS 0, 9.1%; mRS 1, 17.8%; mRS 2,
13.1%; mRS 3, 19.1%; mRS 4, 29.7%; and mRS 5, 11.2%.
Sensitivity and Specificity of BI and mRS
Cutoff Scores
The sensitivity and specificity for the cutoff scores of the BI
in relation to mRS 1, 2, and 3 were calculated (Table 2) and
plotted in ROC curves (Figure).
For mRS 1, the optimal cutoff score on the BI was 95, with
a sensitivity of 85.6% (95% CI, 82.9% to 87.9%) and a
specificity of 91.7% (95% CI, 87.8% to 94.5%). For mRS 2,
the BI score with the highest sum of sensitivity and specific-
ity was 90, with a sensitivity of 90.7% (95% CI, 88.1% to
92.7%) and a specificity of 88.1% (95% CI, 84.6% to 90.9%).
An mRS 3 agreed most with a BI score of 75, with a sensitivity
of 95.7% (95% CI, 93.3% to 97.5%) and a specificity of 88.5%
(95% CI, 85.8% to 90.8%). In all 3 mRS cutoff scores,
sensitivity (rate true unfavorable outcome) increased and
specificity (rate true favorable outcome) decreased when BI
scores increased.
Subsequently, AUCs were calculated. The AUC for the BI
cutoff scores was 0.932 (95% CI, 0.916 to 0.949) in mRS 1,
0.960 (95% CI, 0.949 to 0.971) in mRS 2, and 0.979 (95% CI,
0.972 to 0.985) in mRS 3.
Discussion
In this study, we analyzed the optimal cutoff scores for the BI
and the mRS. These were found to be BI 95 for mRS 1, BI 90
for mRS 2, and BI 75 for mRS 3. This finding may have
TABLE 1. Calculation of Sensitivity and Specificity for BI
Cutoff Scores in mRS 1, 2, and 3
mRS Reflecting
Favorable Outcome
MRS 1, 2, or 3
mRS Reflecting
Unfavorable Outcome







A, indicates true favorable outcome; B, false favorable outcome; C, false
unfavorable outcome; D, true unfavorable outcome.
Sensitivity, D/(DB); specificity, A/(AC).
TABLE 2. Sensitivity, Specificity, and Sum Score for BI Cutoff Scores in mRS 1, 2, and 3
BI score 100 95 90 85 80 75 70 65 60 55 50 45
mRS 1 Sensitivity 0.927 0.856 0.786 0.706 0.660 0.620 0.573 0.529 0.480 0.433 0.390 0.349
Specificity 0.813 0.917 0.935 0.960 0.971 0.978 0.993 0.993 0.996 0.996 0.996 0.996
Sum 1.740 1.773* 1.721 1.666 1.631 1.598 1.566 1.522 1.476 1.429 1.386 1.345
mRS 2 Sensitivity 0.981 0.952 0.907 0.837 0.794 0.750 0.696 0.643 0.585 0.527 0.475 0.425
Specificity 0.651 0.809 0.881 0.939 0.966 0.978 0.993 0.993 0.998 0.998 0.998 0.998
Sum 1.632 1.761 1.788† 1.776 1.760 1.728 1.689 1.636 1.583 1.525 1.473 1.423
mRS 3 Sensitivity 1.000 1.000 1.000 0.991 0.976 0.957 0.917 0.875 0.813 0.745 0.676 0.619
Specificity 0.460 0.596 0.691 0.794 0.846 0.885 0.923 0.948 0.967 0.979 0.984 0.995
Sum 1.460 1.596 1.691 1.785 1.822 1.842‡ 1.840 1.823 1.780 1.724 1.660 1.614
*Maximum sum of sensitivity and specificity in mRS 1; †maximum sum of sensitivity and specificity in mRS 2; ‡maximum sum of sensitivity and specificity in mRS 3.
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consequences for the definition of outcome in acute stroke
trials.
A recent acute stroke trial defined favorable outcome with
an mRS 2 and BI 75.18 According to our results, these
cutoff scores could be suboptimal. The sensitivity (75.0%)
and specificity (97.8%) of these cutoff scores implicates that
25% percent of the patients would have a favorable outcome
according to the BI but an unfavorable outcome according to
the mRS. With regard to the specificity, 2.2% would have an
unfavorable outcome according to the BI but a favorable
outcome according to the mRS. By choosing a BI cutoff score
of 90 (sensitivity 90.7%; specificity 88.1%), the false
favorable outcome rate could be reduced to 9.3%, whereas
the false unfavorable outcome rate would increase to 11.9%.
Minimizing false favorable and false unfavorable outcome
rates could decrease unnecessary heterogeneity of outcome in
acute stroke trials.
Compared with our results, Celani et al found that BI 90
(sensitivity 98%; specificity 97%) was a pivotal score for
which patients did not require help from another person for
everyday activities.14 Kay et al concluded that BI 80
(sensitivity 94%; specificity 80%) was the optimal cutoff
score for self-reported dependency.12 These cutoff scores
differed with those of our study when dependency is consid-
ered to be mRS2, for which the optimal BI score was90.
These differences may be explained by the subjectivity of
self-reported dependency, which will be influenced by per-
sonal circumstances such as socioeconomic status and psy-
chological factors.
The mRS cutoff scores were used as a reference to
distinguish favorable from unfavorable outcome. Although
this is actually not a “gold standard” for dichotomizing
outcome, we think that the mRS is suitable for this purpose.
First, the mRS is a clinically relevant scale, with 6 different
easily understandable and well-defined grades. Second, the
BI is highly correlated with the mRS;19 therefore, we can
compare BI cutoff scores with the mRS. Third, the mRS
measures global disability, whereas the BI scores only ADL.
A point of criticism is that there is only a 5-point difference
between the optimal BI cutoff scores in mRS 1 and mRS 2.
These BI scores are near the maximum score of the BI. This
can be explained by the frequently observed ceiling effects of
the BI.5,6,20 Weimar et al concluded that because of the ceiling
effect, the mRS is preferable to the BI for defining outcome.5
Kwon et al showed that there was no significant difference in
BI scores between mRS 0, mRS 1, and mRS 2 because of
ceiling effects of the BI.19
If the intention of a therapeutic intervention is to obtain
excellent recovery after stroke, which could be defined as
mRS 1, the corresponding BI cutoff score was 95,
according to our results. There is consensus that mRS 2
reflects independence and mRS 2 implicates dependence.21
Our study showed that a BI score 90 is the optimal cutoff
score in relation to mRS 2. In severe strokes, one could
decide to choose mRS 3 and BI 75 as cut-off scores for
favorable outcome. An example of stroke severity–related
outcome has been mentioned by Adams et al.22 They used the
mRS as primary end point, where mRS cutoff scores 0, 1,
or2 reflected favorable outcome, depending on the baseline
National Institutes of Health Stroke Scale (NIHSS) score.
In conclusion, we determined the optimal corresponding BI
and mRS cutoff scores: BI 95 for mRS 1, BI 90 for mRS 2,
and BI 75 for mRS 3. We recommend the use of this/these BI
ROC curves for BI cutoff scores in mRS 1, 2, and 3.
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cutoff score(s) with the corresponding mRS score(s) for
future acute stroke trials in which BI and mRS scores
dichotomize favorable and unfavorable outcome.
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